Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P62330
UPID:
ARF6_HUMAN
Alternative names:
-
Alternative UPACC:
P62330; P26438; Q6FGZ2
Background:
ADP-ribosylation factor 6 (ARF6) is a GTP-binding protein pivotal in regulating endocytic recycling, cytoskeleton remodeling, and mitotic cytokinesis. It plays a crucial role in actin cytoskeleton reorganization, stress fiber formation, dendritic spine development, and membrane trafficking. ARF6 is essential for maintaining adherens junction protein levels, such as CDH1, and is involved in NTRK1 sorting in the recycling pathway.
Therapeutic significance:
Understanding the role of ADP-ribosylation factor 6 could open doors to potential therapeutic strategies.